|
Market Closed -
NYSE
07:03:40 17/10/26 am AEDT
|
After hours 11:00:00 am | |||
| 104.89 USD | +0.20% |
|
105.02 | +0.12% |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 181,500 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -16.69% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 205,439 | 202,457 | 198,767 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -7.57% | -1.45% | -1.82% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 30.9x | 24x | 21x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.79x | 3.63x | 3.44x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -3.48x | 0.8x | 1.5x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.62x | 3.33x | 3.12x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.09x | 3.71x | 3.41x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.8x | 14x | 12.5x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17.5x | 15.6x | 13.9x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 27.2x | 22.7x | 20.7x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.67% | 4.41% | 4.83% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.57 | 2.741 | 2.898 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.45% | 2.61% | 2.76% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.389 | 4.374 | 4.986 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 75.8% | 62.7% | 58.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,198 | 54,525 | 58,249 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,985 | 14,467 | 15,891 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,721 | 13,019 | 14,316 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,162 | 7,843 | 8,710 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 104.89 | 104.89 | 104.89 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/1/22 | 25/1/23 | 24/1/24 | 22/1/25 | 22/1/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 30.95x | 4.09x | 15.82x | 2.45% | 181B | ||
| 20.26x | 3.52x | 12.59x | 2.99% | 116B | ||
| 22.94x | 4.49x | 15.68x | 1.22% | 113B | ||
| 27.35x | 2.68x | 10.75x | 2.64% | 79.83B | ||
| 18.7x | 0.22x | 13.49x | 0.7% | 65.06B | ||
| 31.23x | 7.77x | 20x | 1.28% | 54.35B | ||
| 36.95x | 3.53x | 12.1x | 2.05% | 52.23B | ||
| 37.95x | 9.42x | 26.36x | -.--% | 44.15B | ||
| 34.57x | 6.06x | 19.03x | -.--% | 32.47B | ||
| 38.54x | 3.13x | 11.66x | 0.56% | 32.12B | ||
| Average | 29.94x | 4.49x | 15.75x | 1.39% | 77.07B | |
| Weighted average by Cap. | 28.06x | 4.16x | 15.20x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
















